Table 3.
Relevant study population characteristics.
| Patient ID | Primary tumor site | Highest FIGO stage | Staginga | No. of NACT cycles | NACT responseb | No. of ASC cycles | Recurrence | Disease status | Time to recurrence (months) | Overall follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical (cTNM) | Post-NACT and CRS/HIPEC (ypTNM) | Intracavitary | Lymph nodes | Distant | |||||||||
| 1 | OV | IIIC | cT3c cN0 cM0 | ypT3c ypN1 cM0 | 4 | PD | 2 | — | R-iliac LN | — | DOD | 13.75 | 24.61 |
| 2 | PP | IVB | cT3c cN1 cM1b | ypT3c ypN1 cM1b | 6 | PD | NA | — | — | — | DOC | — | 3.29 |
| 3 | OV | IVA | cT3c cN1 pM1a | ypT3c ypN0 pM1a | 3 | Non-CR/non-PD | 3 | — | Portacaval LN | — | AWD | 37.66 | 56.35 |
| 4 | PP | IVA | cT3c cN1 pM1a | ypT3c ypN1 pM1a | 4 | Non-CR/non-PD | 2 | Loculated ascites, L-abdomen thickening | — | — | DOD | 15.99 | 51.18 |
| 5 | OV | IVA | cT3c cN0 pM1a | ypT3c ypN0 pM1a | 3 | PD | 3 | Pancreatic and L-abdomen implants | — | R-major and minor lung fissures thickening | DOD | 7.93 | 20.43 |
| 6 | OV | IIIC | cT3c cN0 cM0 | ypT3b ypN0 cM0 | 3 | Non-CR/non-PD | 3 | Mass adjacent to spleen, L-paramedian mass, L-external iliac nodule | — | — | DOD | 12.43 | 45.63 |
| 7 | OV | IVB | cT3c cN0 pM1a | ypT3c ypN1a pM1b | 4 | SD | 4 | Mesenteric and anterior abdominal wall nodules | L-external iliac LN | Hepatic metastases | AWD | 18.13 | 45.16 |
| 8 | PP | IIIC | cT3c cN0 cM0 | ypT3c ypN0 cM0 | 3 | PR | 3 | — | Para-aortic LN | Internal mammary LN | DOD | 12.40 | 32.47 |
| 9 | FT | IIIC | cT3c cN0 cM0 | ypT3c ypN1 cM0 | 3 | PR | 3 | Ascites and small peritoneal nodules | — | — | DOD | 11.78 | 18.13 |
| 10 | PP | IIIC | cT3c cN1 cM0 | ypT0 ypN1a cM0 | 3 | Non-CR/non-PD | 3 | Bilateral pelvic sidewall adenopathy | R-iliac and presacral LNs, L-para-aortic and retrocaval LNs | — | DOD | 11.71 | 25.33 |
| 11 | FT | IIIC | cT3c cN0 cM0 | ypT3c ypN1a cM0 | 3 | Non-CR/non-PD | 3 | Ascites and mesenteric enhancement | — | — | DOD | 9.97 | 24.38 |
| 12 | FT | IIIC | cT3c cN0 cM0 | ypT3c ypN1a cM0 | 3 | Non-CR/non-PD | 3 | — | Aortocaval, anterior aortic, L-para-aortic and aortic bifurcation LNs | — | AWD | 10.86 | 34.24 |
| 13 | FT | IVB | cT3c cN0 cM0 | ypT3b ypN0 pM1b | 3 | CR | 3 | — | L-pelvic LN, LLQ and mid abdomen LNs | — | NED | 19.14 | 33.06 |
| 14 | FT | IVB | cT3c cN0 cM0 | ypT3c ypN1a pM1b | 4 | PD | NA | — | — | R-pleural effusion, R-cardiophrenic and epicardial LN | DOD | 6.71 | 33.09 |
| 15 | FT | IIIC | cT3c cN0 cM0 | ypT3c ypN0 cM0 | 3 | SD | 3 | LUQ peritoneal nodule | — | L-epicardial LN | AWD | 13.78 | 31.02 |
| 16 | PP | IIIC | cT3c cN1 cM0 | ypT3c ypN1 cM0 | 3 | SD | NA | Presacral and perirectal densities, porta hepatis thickening, descending and sigmoid colon implants | R-pelvic LN, aortic bifurcation and anterior R-iliac LNs | Two small liver lesions | DOD | 8.22 | 20.53 |
| 17 | PP | IVB | cT3c cN0 cM1b | ypT3a ypN0 cM1b | 4 | PR | 4 | — | LN anterior to the 2nd portion of the dueodenum | — | NED | 29.54 | 29.80 |
| 18 | PP | IIIC | cT3c cN1 cM0 | ypT3a ypN0 cM0 | 4 | Non-CR/non-PD | 3 | — | — | — | NED | — | 25.30 |
| 19 | FT | IVB | cT3c cN0 cM0 | ypT3c ypN1 pM1b | 3 | Non-CR/non-PD | 3 | — | — | — | NED | — | 21.35 |
| 20 | OV | IIIC | cT3c cN1 cM0 | ypT3c ypN1a cM0 | 3 | SD | 3 | Cecal thickening | Posterior aortic and aortocaval LNs, R-pelvic LN | — | AWD | 9.57 | 22.83 |
| 21 | OV | IIIC | cT3c cN0 cM0 | ypT0 ypN0 cM0 | 4 | CR | 2 | — | — | — | NED | — | 22.07 |
| 22 | OV | IVB | cT3c cN1 cM1b | ypT3c ypN1b pM1a | 3 | SD | 3 | — | Para-aortic and aortocaval LNs | L-supraclavicular LN | AWD | 10.10 | 19.80 |
| 23 | FT | IVB | cT3c cN1 cM0 | ypT3c ypN0 pM1b | 3 | SD | 3 | Cecal and anterior pancreatic nodules | — | — | AWD | 9.87 | 18.68 |
| 24 | OV | IVB | cT3c cN1 cM1b | ypT2a ypN1a cM1b | 3 | PR | 3 | LUQ peritoneal nodules | L-iliac LN | — | AWD | 11.55 | 18.39 |
| 25 | FT | IVA | cT3c cN0 pM1a | ypT3c ypN1a pM1a | 6 | Non-CR/non-PD | NA | — | — | — | NED | — | 13.13 |
| 26 | FT | IVB | cT3c cN1 cM1b | ypT2b ypN0 pM1a | 6 | CR | NA | — | R-inguinal, R-para-aortic and multiple bilateral retroperitoneal LNs | L-supraclavicular, R-paratracheal, R-axillary, pretracheal and R-prehilar LNs | DOD | 3.36 | 11.41 |
| 27 | FT | IVB | cT3c cN1 pM1b | ypT3a ypN0 pM1b | 6 | CR | NA | — | Multiples retroperitoneal and pelvic LN | — | AWD | 9.11 | 19.31 |
aAccording to the 8th edition of the American Joint Committee on Cancer TNM staging system, and baccording to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; AWD: alive with disease, CC-Score: completeness of cytoreduction score, CR: complete response, DOC: dead of other cause, DOD: dead of disease, FT: fallopian tube, L: left, LNs: lymph nodes, LUQ: left upper quadrant, NA: not applicable, NACT: neoadjuvant systemic chemotherapy, NED: no evidence of disease, OV: ovarian, PD: progressive disease, PP: primary peritoneal, PR: partial response, R: right, and SD: stable disease